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The carboxy-terminal region of major histocompatibility complex class I (MHC I) molecules is required for the rapid
internalization mediated by Kaposi’s sarcoma-associated herpesvirus (KSHV) proteins K3 and K5. The cytoplasmic tail of
MHC I contains highly conserved serine phosphorylation sites that have been implicated in intracellular trafficking. Indeed,
in vivo labeling experiments reveal a lack of MHC I phosphorylation in K5-transfected HeLa cells. Phosphorylation of the
MHC I tail was restored upon mutation of the PHD/LAP domain of K5. However, deletion and mutation studies of the MHC
I tail show that both K3 and K5 are able to downregulate MHC I lacking the conserved phosphorylation site. This result
suggests that inhibition of phosphorylation reflects, but does not cause, MHC I internalization. Interestingly, K3 and K5 differ
from each other, as well as from human immunodeficiency virus nef, with respect to the minimal MHC I tail sequences
required for MHC downregulation. These data support the notion that K3 and K5 downregulate MHC I molecules by a distinct
molecular mechanism that is different from other viral immune evasion molecules. © 2001 Academic PressKey Words: Kaposi’s sarcoma; KSHV; HHV8; immune escape; major histocompatibility complex class I; intracellular
transport; serine phosphorylation.
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SINTRODUCTION
Cytotoxic T lymphocytes (CTLs) play a central role in
antiviral immunity. Infected target cells are recognized by
CD81 CTLs upon display of virus-derived peptides by
HC I molecules at the cell surface (Townsend and
odmer, 1989). MHC I-bound peptides of eight or nine
mino acids in length are usually generated in the cy-
osol by the ubiquitin proteasome complex and are trans-
ocated into the endoplasmic reticulum (ER) by the pep-
ide transporter TAP (Heemels and Ploegh, 1995). Since
iruses evolved under the selective pressure of the MHC
ystem, they have developed countermeasures against
ntigen presentation. Each and every step of this path-
ay seems to be targeted by one viral species or an-
ther. Members of the herpesvirus family seem to be
articularly ingenious in devising strategies to circum-
ent the MHC I pathway. Herpesviral MHC I inhibitory
echanisms include the inhibition of crucial steps in
ntigen processing such as peptide transport or the
odification of cellular protein transport pathways to
edirect MHC I maturation (reviewed by Fru¨h et al., 1999).
Another virus that sabotages MHC I antigen presen-
ation is the human immunodeficiency virus (HIV). HIV
as developed two different strategies to downregulate1 To whom correspondence and reprint requests should be ad-
ressed. Fax: (503) 418-2701. E-mail: fruehk@ohsu.edu.
369HC I. Newly synthesized MHC I molecules are dis-
osed of in the ER by the HIV protein vpu. Vpu is an-
hored in the ER membrane and binds to the cytoplasmic
omain of MHC class I as well as the cellular protein
omplex b-TrCP (b-transducin repeat-containing protein)
hat targets proteins for degradation (Margottin et al.,
998). Vpu thus connects this protein complex to MHC I
olecules that are not normally degraded by this route.
n addition, HIV mediates the rapid internalization of
HC I via its small multifunctional, cytoplasmic protein
ef (reviewed in Collins and Baltimore, 1999). During this
rocess, MHC I molecules are targeted to the trans-
olgi network (TGN) by an interaction of nef with the
GN protein PACS-1 (Piguet et al., 2000) and rerouting of
HC I occurs via a PI 3-kinase-dependent pathway
Swann et al., 2001).
Recently, two open reading frames encoded by the
gamma-2 herpesvirus Kaposi’s sarcoma-associated her-
pesvirus (KSHV) were also shown to mediate the rapid
internalization of MHC I (Coscoy and Ganem, 2000;
Ishido et al., 2000b) and that of the costimulatory mole-
cules B7-2 and ICAM-1 (Ishido et al., 2000b). KSHV has
een consistently found in Kaposi’s sarcoma (KS), the
ost common AIDS-related malignancy (reviewed in
arid et al., 1999). Similar to HIV-nef, MHC I molecules
seem to be rerouted to the endosomal/lysosomal path-
way. However, K3 and K5 most likely represent ER-resi-
dent molecules that span the ER membrane, whereas
0042-6822/01 $35.00
Copyright © 2001 by Academic Press
All rights of reproduction in any form reserved.
f
i
f
t
i
(
c
t
t
p
T
m
o
t
o
i
T
t
K
T
p
s
m
e
(
s
C
370 PAULSON ET AL.nef is tethered to the plasma membrane. In K3- or K5-
transfected cells, MHC I molecules mature normally and
travel to the cell surface where they are rapidly internal-
ized (Coscoy and Ganem, 2000; Ishido et al., 2000b). The
molecular mechanism by which K3 and K5 regulate the
rapid internalization of MHC I is not known. Interestingly,
replacing the carboxy-terminal portion of CD8 with the
cytoplasmic domain and the transmembrane domain of
MHC I was sufficient to render CD8 molecules suscep-
tible to K3- and K5-mediated degradation (Ishido et al.,
2000a,b). Therefore, it can be assumed that residues in
the MHC I carboxy-terminal region are responsible for
internalization. The MHC I cytoplasmic domain contains
highly conserved residues including a serine phosphor-
ylation site (Guild and Strominger, 1984a; Vega and
Strominger, 1989). The spontaneous internalization of
MHC I seems to require the presence of a full-length
cytoplasmic tail (Capps et al., 1989; Davis et al., 1997;
Vega and Strominger, 1989). This led to the hypothesis
that MHC I internalization is regulated by phosphoryla-
tion (Capps et al., 1989), a theory that was disputed in a
later study (Eichholtz et al., 1992). More recently it was
shown that the lysosomotropic drug primaquine inhibits
MHC I phosphorylation as well as recycling to the cell
surface (Capps and Zuniga, 2000). These data suggest
that phosphorylation either regulates or reflects MHC I
trafficking to and from the cell surface in those cell types
that display spontaneous MHC I internalization. Here we
test the hypothesis that KSHV-K3- and KSHV-K5-medi-
ated MHC I internalization requires signals in the cyto-
plasmic tail of MHC I. Our results show that phosphor-
ylation is inhibited in KSHV-K5-transfected cells. How-
ever, deletion of the cytoplasmic tail does not prevent
K5-mediated MHC I downregulation. Thus, the inhibition
of phosphorylation does not cause MHC I internalization.
Furthermore, the motifs required for MHC I downregula-
tion by K3 or K5 are distinct from those required for
nef-mediated internalization, thus supporting a different
mechanism.
RESULTS
Diminished phosphorylation of MHC I in K5-
transfected HeLa cells
To determine whether the phosphorylation/dephos-
phorylation status of MHC I molecules is changed in K3-
and K5-transfected cells, we amplified KSHV-K3 and
KSHV-K5 DNA by polymerase chain reaction (PCR) using
DNA isolated from KSHV-infected dermal vascular endo-
thelial cells (Moses et al., 1999). The PCR fragments
were cloned under the control of a tetracycline-regulated
promoter and transfected into tet-transactivator-contain-
ing HeLa cells (Gossen and Bujard, 1992). The down-
regulation of MHC I molecules by K3 and K5 was con-
firmed by flow cytometry using the MHC I-specific anti-
body W6/32 (Parham et al., 1979). As shown in Fig. 1A
C
o(top), surface expression of MHC I was greatly dimin-
ished upon transfection of either K3 or K5 constructs. In
transient transfection experiments, only those cells that
had received the expression plasmids showed MHC I
downregulation.
To examine the phosphorylation status of MHC I mol-
ecules, we focused our efforts on KSHV-K5 for reasons
discussed below. We generated stably K5-transfected
HeLa cells. Upon removal of tetracycline, MHC I surface
levels were reduced due to induction of K5 (Fig. 1A,
bottom). Using this stable cell line we performed in vivo
labeling with 33P followed by immunoprecipitation using
W6/32. MHC molecules immunoprecipitated from non-
transfected HeLa cells were clearly phosphorylated (Fig.
1B). In contrast, phosphorylation was significantly re-
duced in cells transfected with K5 (Fig. 1B). These results
suggested that phosphorylation of MHC I was inhibited
by K5. However, the diminished phosphorylation could
simply reflect the reduced amount of MHC I molecules
present in these cells as a consequence of increased
internalization and subsequent lysosomal degradation
(Coscoy and Ganem, 2000; Ishido et al., 2000b). The
overall amount of MHC I molecules in K5-transfected
cells was therefore assessed either by labeling with 35S
or 2 or 16 h prior to immunoprecipitation (Fig. 1C) or by
mmunoblotting MHC molecules from stable K5-trans-
ected HeLa cells (Fig. 1D). These experiments showed
hat the overall amount of MHC I molecules was dimin-
shed in K5 transfectants. Quantification by gel-scanning
Eagle Eye) revealed a twofold reduction of MHC I heavy
hains in K5 transfectants, whereas no difference in
ransferrin receptor amounts was measured. In contrast,
he difference between phosphorylated MHC I and non-
hosphorylated MHC I (Fig. 1B) was more than 10-fold.
herefore we conclude that phosphorylation of MHC I
olecules is inhibited in K5 transfectants. Similarly, we
bserved a reduction of MHC I phosphorylation in K3
ransfectants (not shown). However, the overall reduction
f MHC I molecules due to degradation was not signif-
cantly different from the reduction of phosphorylation.
herefore, we could not distinguish experimentally be-
ween degradation and inhibition of phosphorylation in
3 transfectants.
he PHD/LAP domain is required to inhibit MHC I
hosphorylation
The primary structure of K3 and K5 reveals a con-
erved amino-terminal domain that contains a sequence
otif known as the plant homeodomain (PHD) (Aasland
t al., 1995) or leukemia-associated protein (LAP) domain
Saha et al., 1995). The PHD/LAP finger consensus
equence is represented by C1-Xaa1-2-C2-Xaa9-21-
3-Xaa2-4-C4-Xaa4-5-H5-Xaa2-C6-Xaa2-C8 (abbreviated
ys4-His-Cys3), with numbers representing the numbers
f amino acid residues between the conserved cysteine
i
p
W
b
o
tated with W6/32, and analyzed by SDS–PAGE. (D) Western blot anal-
ysis of MHC I expression in cells stably expressing K5. Lysates from
371KSHV-K5 INHIBITS PHOSPHORYLATION OF MHC I CYTOPLASMIC TAILand histidine residues. Point mutations in the PHD/LAP
domain of human proteins are associated with genetic
diseases (Gibbons et al., 1997; Lu et al., 1998). The
sequence conservation of the PHD/LAP domains sug-
gests that they play a crucial role either in MHC down-
regulation or in the subcellular localization of K3 and K5.
The recently determined solution structure of a PHD/LAP
domain revealed an interlaced type of zinc finger
whereby the highly conserved cysteine and histidine
residues form a complex with two zinc atoms (Pascual et
al., 2000). To test whether the PHD/LAP domain is re-
quired for the observed lack of phosphorylation in HLA
molecules, we replaced the first two cysteines of the
PHD/LAP motif with serines in the K5 sequence by site-
directed mutagenesis. Equivalent mutations were shown
to destroy the zinc-binding properties in other proteins
(Blumberg et al., 1987). Replacement of the two residues
in K5 was confirmed by sequence analysis.
Upon transfection into HeLa cells, the PHD mutant
was unable to affect the phosphorylation status of MHC
I (Fig. 2A). The mutant protein was also unable to reduce
MHC I surface expression (Fig. 1). It was possible that
these point mutations resulted in a mislocalization or
misfolding and rapid degradation of mutant K5. There-
fore, we examined the stability of mutated K5 by pulse–
chase labeling followed by immunoprecipitation using
K5 constructs that were FLAG-epitope-tagged at their
carboxy-terminus. Previously it was shown that such
tagging does not affect the function of K5 (Coscoy and
Ganem, 2000). As shown in Fig. 2B, the mutations did not
prevent expression of K5. We further examined the intra-
cellular localization of mutated K5 by immunofluores-
cence microscopy. Both wildtype and mutant K5 colocal-
ized with calreticulin in the ER (Fig. 3). However, a portion
of the mutant protein stained separately from calreticulin,
suggesting that the K5 mutant had a slightly altered
intracellular localization compared to wildtype K5. We do
not know whether this subtle change in intracellular
location plays a role in the malfunction of the mutant
protein. The ER localization of the wildtype protein is in
agreement with previous observations in HeLa cells
(Coscoy and Ganem, 2000), but contrasts with a surface
localization described for BJAB cells (Ishido et al.,
2000b). We conclude that the PHD/LAP domain is essen-
tial for K5-mediated internalization of MHC I molecules,
consistent with its role in the internalization of B7 and
ICAM-1 (Ishido et al., 2000a).
HeLa-tet TA cells and K5 stable cells were immunoblotted with either
an MHC I-specific antiserum (K455) or a transferrin receptor-specificFIG. 1. KSHV K5 inhibits MHC I phosphorylation. (A) The KSHV
proteins K3 and K5 significantly decrease surface expression of MHC
I, and the PHD/LAP domain of K5 is required for this downregulation.
HeLa-tet TA cells were transiently transfected with FLAG-tagged K3,
K5, or K5 PHD/LAP mutant expression plasmids or stably transfected
with a tetracycline-repressible FLAG-tagged K5 expression plasmid. At
48 h posttransfection (or, for the K5 stable cell line, 48 h postinduction
of K5 expression by removal of tetracycline), the cells were stained with
the monoclonal FITC-conjugated anti-MHC I antibody W6/32 (Sigma)
and analyzed by FACS. Untransfected HeLa-tet TA cells served as a
positive control for MHC I expression. The dotted line represents
unstained cells. The two peaks evident in the K3 and K5 transient
transfections correspond to transfected (low-level MHC I expression)
and untransfected (high-level MHC I expression) cells. (B) MHC I
phosphorylation is drastically reduced in K5 stable cells. HeLa-tet TA
cells and K5-FLAG stable cells were labeled with [33P]orthophosphate
n phosphate-free medium and lysed in buffer containing protease and
hosphatase inhibitors. Immunoprecipitations were performed with the
6/32 monoclonal antibody, and the MHC I complexes were analyzed
y SDS–PAGE. Two independent experiments are shown side by side
n the 33P gel. (C) [35S]Methionine metabolic labeling and MHC I
immunoprecipitation analysis indicate that the reduced phosphoryla-
tion of MHC I molecules in the K5 stable cells is not merely a reflection
of MHC I degradation. HeLa-tet TA cells and K5 stable cells were
labeled with [35S]methionine for either 2 h or overnight, immunoprecipi-antibody (anti-human CD71). The bands were quantified with the Eagle
Eye system (Stratagene).
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372 PAULSON ET AL.Different regions of the MHC I cytoplasmic tail are
required for phosphorylation and K5- or K3-mediated
internalization
MHC I molecules are not phosphorylated until they
reach the cell surface. Specifically, phosphorylation is
absent from MHC molecules before they traverse the
Golgi apparatus (Loube et al., 1983). Moreover, MHC I
molecules remain phosphorylated upon internalization
and recycling, whereas inhibition of recycling by prima-
quine inhibits phosphorylation (Capps and Zuniga, 2000).
However, it is not clear whether dephosphorylation sim-
ply reflects the inhibition of MHC I recycling or whether
there is a causative relationship between recycling and
phosphorylation. Further complicating these issues are
observations that suggest that the phosphorylation and
dephosphorylation of MHC I are cell type-dependent
(Capps et al., 1989). To examine whether or not the
FIG. 2. Mutation of the PHD/LAP domain of K5 restores MHC I
phosphorylation. (A) Cells expressing the wildtype K5-FLAG protein
show reduced MHC I phosphorylation, while cells expressing the
K5-FLAG PHD/LAP mutant protein display normal MHC I phosphory-
lation. HeLa-tet TA cells were transiently transfected with the wild-type
or PHD/LAP mutant K5-FLAG constructs or left untransfected. At 48 h
posttransfection, the cells were labeled with either [33P]orthophosphate
r [35S]methionine, lysed, and immunoprecipitated with the W6/32 an-
tibody. The immune complexes were analyzed by SDS–PAGE. (B) The
K5-FLAG PHD/LAP domain mutant protein is expressed normally.
HeLa-tet TA cells were transfected with either the wild-type or mutant
K5-FLAG plasmid. At 72 h posttransfection, the cells were labeled with
[35S]methionine in methionine-free medium for 30 min and chased with
egular medium for either 0 or 3 h. At this point, the cells were lysed,
nd immunoprecipitations were performed with the FLAG M2 mono-
lonal antibody. The immunoprecipitates were then analyzed by SDS–
AGE. MW, molecular weight markers. The K5-FLAG protein is 36 kDa.observed inhibition of phosphorylation in K5-transfected
cells is important for the internalization of MHC I mole-
d
tcules, we generated a set of mutants in the cytoplasmic
tail of the human MHC I molecule HLA-A2.1.
The series of mutants generated is shown in Table 1.
The two mutants with tail deletions corresponding to
exon 6 and exon 7 of HLA-A2.1 were described previ-
ously (Le Gall et al., 1998). The other mutants were
generated by PCR-directed mutagenesis. In mutants
TM1–TM4, serines that are potentially phosphorylated
were mutated in groups of two. Mutants d311–d331 were
generated by truncating HLA-A2.1 and simultaneously
adding the HA tag to the carboxy-terminus. All mutations
were verified by sequence analysis.
To analyze whether or not the resulting constructs
could be phosphorylated, we transfected cells with the
respective constructs followed by [33P]orthophosphate
labeling and immunoprecipitation with BB7.2, an anti-
body specific for HLA-A2.1 (Parham and Brodsky, 1981).
Since HeLa cells do not express endogenous HLA-A2.1,
only transfected molecules will be recovered. To control
for expression, we performed metabolic labeling with
[35S]methionine in parallel. The results are shown in Fig.
. Expression of all constructs was comparable and
eadily detectable (Fig. 4, bottom). Moreover, all con-
tructs were transported to the cell surface (see below).
owever, the amount of phosphorylation differed signif-
cantly depending on the construct (Fig. 4, top). All con-
tructs that contained the two carboxy-terminal serines
ere strongly phosphorylated. Removal of these two
erines either by point mutation (TM4) or by deletion
utagenesis (d331) resulted in a greatly diminished
hosphorylation. However, complete loss of phosphory-
ation was observed only when six of the eight serines
ere removed by deletion (d318). These results are con-
istent with the observation that the main phosphoryla-
ion site of MHC I is serine 335, which was removed in
utant TM4 (Guild and Strominger, 1984b). However,
hey also show that additional, albeit weaker, phosphor-
lation can take place at other conserved serines within
he cytoplasmic tail.
To test which of these mutants could still be down-
egulated by KSHV-K5 and KSHV-K3, we cotransfected
ach mutant construct or vector control (pBI) and ana-
yzed the surface expression of HLA-A2.1 by flow cytom-
try. To distinguish between transfected and nontrans-
ected cells, we further cotransfected an expression con-
truct for green fluorescent protein. The results are
ummarized in Table 1. Surprisingly, all mutant HLA-A2.1
onstructs were downregulated by K5. In contrast, K3
as unable to downregulate d311, which carries the
hortest cytoplasmic tail. The different capability of K3
nd K5 to downregulate mutants d311 and d318 is also
hown in Fig. 5 by plotting the anti-HLA-A2.1 fluores-
ence against the GFP fluorescence. A clear reduction of
318 HLA-A2.1-positive cells was observed upon co-
ransfection with K3 and K5, whereas no effect on GFP
ary Ale
s
373KSHV-K5 INHIBITS PHOSPHORYLATION OF MHC I CYTOPLASMIC TAILfluorescence was observed. In contrast, d311 fluores-
cence was reduced by K5 but not by K3. These results
suggest (a) that neither K3 nor K5 requires any parts of
the cytoplasmic tail that are phosphorylated in order to
downregulate MHC I and (b) that K3 and K5 differ in their
requirement for the involvement of the cytoplasmic tail of
MHC I. Whereas K3 requires a short stretch of HLA-A2.1-
specific cytoplasmic tail amino acids, K5 is able to down-
regulate MHC I that almost completely lacks the HLA-
A2.1-specific cytoplasmic tail. We conclude that the inhi-
bition of MHC I phosphorylation is a result of the
increased internalization of MHC I molecules but does
not cause it.
FIG. 3. The PHD/LAP domain mutant of K5 primarily localizes to the ER
constructs. The transfected cells were stained with a primary FLAG an
calreticulin antibody (calreticulin is an ER-specific protein) and a second
microscope.
T
Mean Immunofluorescence of HLA-A2.1 Tail M
Construct HLA-A2.1 Tail sequence
A2 RRKSSDRKGGSYSQAASSDSAQGSDVSLTA
d311 RRK-HA
d318 RRKSSDRKGG-HA
d324 RRKSSDRKGGSYSQAA-HA
d331 RRKSSDRKGGSYSQAASSDSAQG-HA
TM1 RRKAADRKGGSYSQAASSDSAQGSDVSLTA
TM2 RRKSSDRKGGAYAQAASSDSAQGSDVSLTA
TM3 RRKSSDRKGGSYSQAASADAAQGSDVSLTA
TM4 RRKSSDRKGGSYSQAASSDSAQGADVALTA
D6 RRKSS-----------SSDSAQGSDVSLTA
D7 RRKSSDRKGGSYSQAA--------------Note. Experiments were performed as described in the legend to Fig. 5. M
hown in boldface type.DISCUSSION
The observation that MHC I phosphorylation is inhib-
ited in K5-transfected cells is most likely the result of a
series of events: MHC I molecules travel to the cell
surface normally, but are rapidly internalized. Normal exit
and rapid internalization have been well documented
previously (Coscoy and Ganem, 2000; Ishido et al.,
2000b). Internalized MHC I molecules are not degraded
immediately, but dwell in endosomal vesicles before
being degraded in lysosomes. This conclusion is sup-
ported by the fact that the half-life of MHC I molecules in
K3- and K5-transfected cells is several hours, whereas
-tet TA cells were transiently transfected with the K5 wildtype or mutant
and secondary Alexa 488 (green) antibody, as well as with a primary
xa 568 (red) antibody. The stained cells were examined with a confocal
Cotransfected with Vector Plasmid, K3 or K5
pBI KSHV-K3 KSHV-K5
292 44 38
192 171 38
188 33 21
159 29 22
151 34 27
176 30 26
184 35 22
205 34 28
208 37 24
202 40 25
162 31 18. HeLa
tibodyABLE 1
utants
CKV
CKV
CKV
CKV
CKV
CKV
---Vean immunofluorescence values that reflect MHC downregulation are
i B7.2. T
1
374 PAULSON ET AL.the internalization takes place rapidly within minutes
(Coscoy and Ganem, 2000; Ishido et al., 2000b; and
unpublished observations). Thus, the main part of the
MHC I population resides in intracellular vesicles. There-
fore, it seems likely that the dephosphorylated popula-
tion described here represents internalized MHC I mol-
FIG. 4. Deletion mapping of MHC I phosphorylation sites. Analysis of
proteins. The cytoplasmic tail sequences of the various mutants are sho
constructs. At 48 h posttransfection, the cells were labeled with either [
mmunoprecipitated with the HLA-A2.1-specific monoclonal antibody B
0–20% gradient gels.
FIG. 5. Deletion of phosphorylation sites does not prevent MHC I
downregulation by KSHV K3 and KSHV K5. HeLa-tet TA cells were
transiently transfected with the HLA A2.1 wildtype or mutant constructs,
along with pBI (vector plasmid), K3, or K5, as well as with 10-fold less
GFP expression plasmid. At 48 h posttransfection, the cells were
stained with a primary mouse anti-human HLA-A2.1 monoclonal anti-
body (BB7.2) followed by a secondary PE-conjugated anti-mouse IgG
antibody and then analyzed by FACS. Cells were gated on GFP and
analyzed for PE staining (A2.1 expression). The FACS dot plots for the
A2, d311, and d318 constructs are shown; the FACS results for the other
mutants are presented in Table 1.ecules destined for degradation. This interpretation
would be consistent with the observation that inhibition
of intracellular degradation by primaquine also results in
the accumulation of a dephosphorylated population of
MHC I molecules (Capps and Zuniga, 2000). These au-
thors further concluded that the MHC I molecules remain
phosphorylated if they recycle back to the cell surface,
but are dephosphorylated if they are destined for degra-
dation. Therefore, we conclude that the dephosphory-
lated MHC I molecules in K5-expressing cells (and most
likely also in K3-transfected cells) represent an interme-
diate between internalization and degradation.
Our data further indicate that the K3- and K5-mediated
internalization also occurs in the absence of the phos-
phorylation sites in the MHC I tail suggesting that the
inhibition of MHC I tail phosphorylation is indicative of
MHC I internalization by the viral proteins, but not caus-
ative. The result that the cytoplasmic tail of MHC I is not
required for K5-mediated internalization also shows that
the internalization mechanism is quite distinct from that
of nef. The two HLA-A2.1 mutants D6 and D7 were pre-
viously used to map the sites required for nef-mediated
internalization (Le Gall et al., 1998). The cytoplasmic tail
is encoded by two distinct exons that are deleted in
these mutants. It was found that the exon 6-deleted
mutant was no longer internalized in the presence of nef,
in contrast to the exon 7-deleted mutant. However, nei-
ther K3 nor K5 required this internalization signal to be
present for MHC I downregulation. Furthermore, hybrids
between the MHC I carboxy-terminal domain, including
the transmembrane domain and the cytoplasmic domain,
with the luminal domain of CD8 were still downregulated
ression and phosphorylation status of the different HLA-A2.1 tail mutant
able 1. HeLa-tet TA cells were transiently transfected with the indicated
ophosphate or [35S]methionine. After the labeling, cells were lysed and
he immunoprecipitated complexes were analyzed by SDS–PAGE onthe exp
wn in T
33P]orthby K3 and K5 (Ishido et al., 2000b). Taken together with
our data, it seems that the minimal signals required for
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375KSHV-K5 INHIBITS PHOSPHORYLATION OF MHC I CYTOPLASMIC TAILK5-mediated internalization reside mostly in the trans-
membrane domains of MHC I. In contrast, K3 seems to
require an additional stretch of amino acids in the HLA-
A2.1 cytoplasmic region. Previous observations also in-
dicated that K3 and K5 differ with respect to their allele
specificity. Whereas K3 did not discriminate between
human alleles, K5 showed a preference for HLA-A and
HLA-B alleles. Our mapping experiments indicate that
the allele specificity of K5 could not be caused by se-
quences in the cytoplasmic domain since all three hu-
man alleles are identical in the minimal cytoplasmic
region mapped in this study. However, HLA alleles differ
in their transmembrane domain, thus further supporting
a pivotal role of the transmembrane domain for K5-
mediated MHC downregulation. A possible explanation
for this role is that K5 and K3 may interact at some point
with MHC I molecules (either directly or indirectly). This
interaction would most likely involve specific regions in
the transmembrane domain and, at least for K3, the
membrane-proximal domain of the MHC I tail. However,
such an interaction still needs to be demonstrated.
Therefore, it can only be speculated by what molecular
mechanism K3 and K5 induce the internalization of MHC
I molecules. If the two viral proteins are strictly ER-
resident, as most current data, including ours, seem to
suggest, one could speculate that the viral proteins in-
troduce a modification into the MHC I transmembrane
domain and membrane-proximal cytoplasmic domain
that serves as an internalization signal. Work is in
progress to detect such a modification. Alternatively, the
viral proteins could employ a cellular protein to act on
this region of the MHC I molecule. Either case repre-
sents an entirely novel molecular mechanism to escape
immune detection by cytotoxic T cells.
MATERIALS AND METHODS
Construction of plasmids
The K3 and K5 open reading frames were both PCR-
amplified with Vent polymerase, using genomic DNA
from KSHV-infected endothelial cells as a template. The
C-terminal FLAG-tagged K3 PCR product was generated
with the following primers: 59 K3 Nhe, 59-GGC-GGC-TAG-
AT-GGA-AGA-TGA-GGA-TGT-TCC-39; 39 K3 C-FLAG,
9-GTC-GCC-CGG-GTC-ACT-TGT-CGT-CGT-CGT-CCT-TGT-
GT-CAT-GAA-ACA-TAA-GGG-CAG-39. This PCR product
as cloned into the PCR-blunt vector (Invitrogen, Carls-
ad, CA) and cut out with NheI and SpeI. The SpeI site
as blunted with Klenow, allowing this fragment to be
loned between the NheI and EcoRV sites of the pBI
etracycline-regulated expression plasmid (Clontech,
alo Alto, CA). All of the plasmids were confirmed by
equencing.
The C-terminal FLAG-tagged K5 PCR product was also
enerated by PCR with Vent polymerase, using genomic
NA from KSHV-infected endothelial cells and the fol-
A
Cowing PCR primers: 59 K5 Nhe, 59-GGC-GGC-TAG-CAT-
GC-GTC-TAA-GGA-CGT-AGA-39; 39 K5 C-FLAG, 59-GTC-
GA-TAT-CTC-ACT-TGT-CGT-CGT-CGT-CCT-TGT-AGT-CAC-
GT-TGT-TTT-TTG-GAT-GA-39. This PCR fragment was
nitially cloned into the PCR-blunt vector (Invitrogen), cut
ut with NheI and EcoRV, and cloned between the NheI
nd EcoRV sites of the pBI vector (Clontech).
The FLAG-tagged K5 PHD/LAP mutant plasmid was
enerated using the QuikChange site-directed PCR mu-
agenesis kit (Stratagene, La Jolla, CA). To convert the
irst two conserved cysteines in the PHD/LAP motif into
erines, PCR was performed on K5-FLAG/pBI plasmid
NA with Pfu-turbo and the following mutagenic primers:
9 K5 CmS, 59-GAG-GGA-CCC-ATC-TCC-TGG-ATA-
CC-AGG-GAA-GAG-GTG-39; 39 K5CMS, 59-CAC-CTC-
TC-CCT-GGA-TAT-CCA-GGA-GAT-GGG-TCC-CTC-39. The
61-bp NheI/XmnI fragment of K5 containing these mu-
ations, as well as the XmnI/BglII fragment of K5-FLAG/
BI, was joined in a three-part ligation between the NheI
nd BglII sites of the pBI vector.
To make the wildtype HLA-A2.1 construct, the EcoRI/
baI fragment of A2.1 (from bp 429 to 2285), which in-
ludes the open reading frame as well as some addi-
ional flanking sequence, was cloned between the EcoRI
nd XbaI sites of the tetracycline-regulated vector
UHD10.1 (Gossen and Bujard, 1992). The A2.1 tail dele-
ion constructs were generated by PCR amplification,
ith Vent polymerase, from the wildtype A2.1 plasmid.
he constructs were truncated at bp 1442 (aa 311), bp
463 (aa 318), bp 1481 (aa 324), or bp 1502 (aa 331). The
CR product included a natural StuI site (bp 1212 of A2.1)
ear the 59 end, the indicated amount of A2.1 sequence,
nd a C-terminal HA tag as well as an engineered SphI
ite (bp 1553) in the 39 primer. The same 59 primer (59
2Stu, bp 1188 of A2: 59-GAC-ACG-GAG-CTC-GTG-GAG-
C-39) was used along with each of the four 39 primers
39 A2d1442 (d311): 59-GTC-GGC-ATG-CTC-AGG-CGT-
GT-CGG-GCA-CGT-CGT-AGG-GGT-ACT-TCC-TCC-TCC-
CA-TCA-CAG-39; 39 A2d1463 (d318): 59-GTC-GGC-ATG-
TC-AGG-CGT-AGT-CGG-GCA-CGT-CGT-AGG-GGT-
CC-CTC-CTT-TTC-TAT-CTG-AGC-39; 39 A2d1481 (d324):
9-GTC-GGC-ATG-CTC-AGG-CGT-AGT-CGG-GCA-CGT-
GT-AGG-GGT-ATG-CAG-CCT-GAG-AGT-AGC-TCC-39; 39
2d1502 (d331): 59-GTC-GGC-ATG-CTC-AGG-CGT-AGT-
GG-GCA-CGT-CGT-AGG-GGT-AGC-CCT-GGG-CAC-TGT-
AC-TGC-39] to generate the various deletions. The PCR
ragment was initially cloned into PCR-blunt, cut out with
tuI and SphI, and cloned between the StuI and SphI
ites of A2.1/pUHD10.1.
The TM1, TM2, TM3, and TM4 mutants were made
sing a PCR-based strategy described previously
Swann et al., 2001) with the following mutant primers:
M1, 39-GCTCCCTCCTTTTCTATCTGCGGCCTTCCTCCT-
CACATCACAGC; TM1, 59-GCTGTGATGTGGAGGAGGA-
GGCCGCA-GATAGAAAAGGAGGGAGC; TM2, 39-GTCA-
TGCTTGCAGCCTGAGCGTAGGCCCCTCCTTTTCTATC-
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376 PAULSON ET AL.TGAGC; TM2, 59-GCTCAGATAGAAAAGGAGGGGCCTA-
CGCTCAGGCTGCAAGCAGTGAC; TM3, 39-CACATCAGA-
GCCCTGGGCAGCGTCAGCGCTTGCAGCCTGAGAGTA-
GC; TM3, 59-GCTACTCTCAGGCTGCAAGCGCTGACGCT-
GCCCAGGGCTCTGATGTG; TM4, 39-CACTTTACAAGCT-
GTGAGAGCCACATCAGCGCCCTGGGCACTGTCAC-
TGC; and TM4, 59-GCAGTGACAGTGCCCAGGGCGCTGA-
TGTGGCTCTCACAGCTTGTAAAGTG).
Briefly, 59 and 39 overlapping mutant fragments were
synthesized in separate reactions. Then, in a second
reaction, the fragments were mixed and the full-length
fragment was amplified. The primers used to make the 59
fragment were as follows: upstream primer (59-GCAGCT-
CAGACCACCAAGCACAAG-39) and a 39 mutant primer.
The primers used to make the 39 fragment were as
follows: downstream primer (59-TAGAAGGCACAGTC-
GAGG-39) and a 59 mutant primer. In the second PCR, the
overlapping mutant fragments were mixed together with
upstream and downstream primers. The resulting frag-
ment was digested with XhoI and PmlI and cloned back
into the HLA-A2-pcDNA expression vector (obtained
from Dr. Hidde Ploegh’s laboratory). The resulting con-
struct was sequenced to ensure that only the intended
alteration had been made.
The A2D6 and A2D7 constructs (Le Gall et al., 1998)
were kindly provided by Olivier Schwartz.
Cell culture and transient transfections
HeLa-tet TA cells were maintained in DMEM with 10%
tet-free FCS (Clontech), glutamine, pen/strep/antifungal
drug (Gibco BRL, Rockville, MD), and 100 mg/ml G418
(Calbiochem, San Diego, CA). Transfections were per-
formed using the Effectene kit (Qiagen, Valencia, CA).
The day before transfections, 106 cells were plated in
00-mm tissue culture dishes. Cells were transfected
ith a total of 2 mg DNA per 100-mm dish, according to
the standard adherent cell transfection protocol outlined
in the Effectene kit handbook. For GFP cotransfections,
10-fold less GFP plasmid was used, to ensure that the
GFP-positive cells would also contain the other plas-
mid(s) of interest. Six to 18 h after transfections, cells
were washed once with PBS and given fresh medium. At
48 h posttransfection, cells were trypsinized, if neces-
sary, and utilized in the assay of interest.
Generation of the K5 stable cell line
HeLa-tet TA cells were transfected using a calcium
phosphate kit (Invitrogen). The K5 C-FLAG/pBI plasmid
was linearized with FspI, and a plasmid carrying resis-
tance to Ouabain (Fru¨h et al., 1994) was linearized with
ScaI; the linearized plasmids were then purified using
the QIAquick PCR purification kit (Qiagen). Cotransfec-
tions were performed with 20 mg of linearized K5 C-LAG/pBI and 1 mg of linearized Ouabain resistance
plasmid, or, as a control, with the linearized Ouabain
i
tresistance plasmid alone. The transfected cells were
grown in medium containing 1 mg/ml tetracycline, to
repress expression of K5-FLAG. Three days posttrans-
fection, the cells were trypsinized and split at ratios of
1:3, 1:6, and 1:9 in 100-mm dishes. Twice a week, the
cells were exposed overnight to medium containing 1
mM Ouabain, to kill the nontransfected cells. Two and a
half weeks later, when sizable colonies were readily
apparent on the plates, cloning rings were used to iso-
late individual cell clones and expand them in 12-well
plates. To screen for tetracycline-repressible K5 expres-
sion, cells were washed three times with PBS to remove
tetracycline, grown in either tetracycline-free or tetracy-
cline-containing medium for 2 days, and analyzed by
FACS for MHC I. Expression of K5-FLAG was then con-
firmed by immunofluorescence and immunoprecipita-
tions with the FLAG M2 monoclonal antibody (Sigma, St.
Louis, MO).
Flow cytometry
A total of 7.5 3 105 detached cells were washed two
imes with PBS and resuspended in a blocking solution
f 10% human serum in calcium/magnesium-free PBS for
5 min on ice. The cells were stained with the primary
ntibody in blocking solution for 25 min on ice and
ashed with PBS. Then, if necessary, cells were stained
ith a secondary PE-conjugated anti-mouse IgG anti-
ody (Sigma) for 25 min on ice. The stained cells were
ashed twice with PBS and fixed with 1% formaldehyde
n PBS. To assess expression of MHC I on HeLa-tet TA
ells, the W6/32 mouse anti-human Class I monoclonal
ntibody (Sigma) was utilized (either the FITC-conju-
ated form or, for GFP cotransfections, the unconjugated
orm—10 ml of antibody was sufficient to stain 106 cells).
o detect HLA A2.1, the mouse monoclonal antibody
B7.2 was used at a final concentration of 10 mg/ml. A
E-conjugated anti-mouse IgG antibody (Sigma), diluted
:100, served as a secondary detection reagent. FACS
nalysis was performed on a Becton Dickinson FACScan
low cytometer (Bedford, MA) with CellQuest software.
33P labeling and immunoprecipitations
HeLa-tet TA cells, K5/HeLa-tet TA stable cells, and
ransfected HeLa-tet TA cells were grown to 90% conflu-
ncy in 100-mm tissue culture dishes, placed in phos-
hate-free medium (Gibco BRL, Rockville, MD) for 1 h,
nd labeled with 500 mCi of [33P]orthophosphate (NEN,
oston, MA) in 1 ml of phosphate-free medium for 2 h.
he labeled cells were placed on ice, washed twice with
old PBS (supplemented with phosphatase inhibitors),
nd lysed for 1 h with 1 ml of a 1% Triton X-100/PBS buffer
ontaining protease inhibitor tablets (Roche, Indianapo-
is, IN) and a cocktail of serine/threonine phosphatase
nhibitors (Sigma). The cell lysates were immunoprecipi-
ated with either 15 ml (3 mg) of the W6/32 mouse anti-
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the mouse anti-human HLA A2 monoclonal antibody
BB7.2 (obtained from Didier LeTurq). The immune com-
plexes were bound to protein A–Sepharose (Amersham
Pharmacia Biotech, Piscataway, NJ), washed three times
in wash buffer (containing 0.1% Triton X-100, protease
inhibitor tablets, and phosphatase inhibitor cocktail), and
resuspended in 23 SDS sample buffer (Invitrogen) (sup-
plemented with 0.2 M DTT. The immunoprecipitated
complexes were then heated at 55°C for 5 min and
analyzed by SDS–PAGE on 10–20% Tris–glycine gradient
gels (Invitrogen). The gels were fixed, dried, and exposed
to film using a Kodak BioMax Transcreen-LE intensifying
screen.
35S labeling and immunoprecipitations
Cells were grown to 90% confluency in 100-mm tissue
ulture dishes, exposed to methionine-free medium
Gibco BRL) for 30 min, and labeled with 400 mCi of 35S
protein labeling mix (NEN) in 1 ml of methionine-free
medium for 30 min (or for 2 or 16 h as indicated). (In the
overnight labeling experiments, 1% FCS was also in-
cluded in the medium.) After the labeling, cells were
washed twice with PBS and either lysed directly, in PBS
containing 1% Triton X-100 and protease inhibitor tablets
(Roche), or chased with regular medium for the indicated
times and then lysed. The cell lysates were immunopre-
cipitated with 15 ml (3 mg) of the W6/32 mouse anti-
human Class I monoclonal antibody (Sigma), 5 mg of the
LAG M2 monoclonal antibody (Sigma), or 5 mg of the
HLA A2 monoclonal antibody BB7.2 (obtained from Didier
LeTurq). The immunoprecipitated complexes were bound
to protein–Sepharose or protein G–Sepharose (Amer-
sham Pharmacia Biotech), washed three times in wash
buffer (containing 0.1% Triton X-100 and protease inhibi-
tor tablets), and resuspended in 23 SDS sample buffer
(Invitrogen) supplemented with 0.2 M DTT. The immuno-
precipitated complexes were then boiled for 5 min and
analyzed by SDS–PAGE on 10–20% Tris–glycine gradient
gels (Invitrogen). The gels were fixed, dried, and exposed
to film as above.
Immunofluorescence
HeLa-tet TA cells were transiently transfected with the
wildtype or mutant K5-FLAG construct. At 48 h posttrans-
fection, the cells were detached with cell dissociation buffer
(Gibco BRL) and grown overnight on tissue culture-treated
glass coverslips (Becton Dickinson) in 6-well plates. The
following day, the cells were fixed with 4% formaldehyde in
calcium/magnesium-free PBS, quenched with 50 mM
NH4Cl in PBS, and permeabilized with 0.1% Triton X-100 in
BS. Antibody staining was carried out in PBS containing
% fetal calf serum. The FLAG M2 mouse monoclonal
ntibody (Sigma) was used at a dilution of 1:250, to detect
he FLAG-tagged K5 proteins. The rabbit anti-human calre-iculin antibody (StressGen, Victoria, British Columbia, Can-
da) was used at a 1:200 dilution. A secondary 488 Alexa
luorophore-conjugated anti-mouse IgG F(ab9)2 antibody
Molecular Probes, Eugene, OR) was used at a concentra-
ion of 4 mg/ml to detect the primary FLAG antibody, while
a secondary 568 Alexa fluorophore-conjugated anti-rabbit
IgG antibody (Molecular Probes) was utilized at 4 mg/ml for
the detection of the primary calreticulin antibody. The cov-
erslips were mounted on slides using Gel-Mount (Biomeda,
Foster City, CA), and the stained cells were examined by
confocal microscopy.
Immunoblots
Cells were grown to 90% confluency in 100-mm tissue
culture dishes, trypsinized, and counted. A total of 5 3
106 cells were lysed in 250 ml of 23 SDS sample buffer
containing 0.2 M DTT and boiled for 10 min. The lysates
were run over Qiashredder columns (Qiagen). Then 12 ml
f the lysate was run on a 10–20% Tris–glycine gel
Invitrogen) with 13 Tris–glycine–SDS running buffer,
nd the separated proteins were transferred to a
.45-mm nitrocellulose membrane (Bio-Rad, Hercules,
A). The Western blots were carried out using the Im-
un-Star chemiluminescent alkaline phosphatase kit
Bio-Rad), except that 5% nonfat dry milk in TBS and
TBS was used instead of the recommended 0.2%. For
etection of MHC I, the polyclonal rabbit antibody K455
as used, at a dilution of 1:2000, followed by a second-
ry alkaline phosphatase-conjugated anti-rabbit Ig anti-
ody, diluted 1:3030. For detection of the transferrin re-
eptor, a monoclonal mouse anti-human CD71 antibody
BD PharMingen, Hercules, CA) was utilized at a 1:500
ilution, followed by a secondary alkaline phosphatase-
onjugated anti-mouse Ig antibody, diluted 1:3030.
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